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Abstract Apolipoprotein AV (apoAV) overexpression causes
a decrease in plasma triglyceride (TG) levels, while deficiency
of apoAV causes hypertriglyceridemia in both men and
mice. However, contrary to what would be expected, plasma
apoAV and TG levels in humans are positively correlated.
To address this apparent paradox, we determined plasma
apoAV levels in various mouse models with median TG lev-
els ranging from 30 mg/dl in wild-type mice to 2089 mg/dl
in glycosylphosphatidylinositol-anchored HDL binding pro-
tein 1-deficient mice. The data show that apoAV and TG lev-
els are positively correlated in mice (r510.798, P, 0.001).
In addition, we show that LPL gene transfer caused a simul-
taneous decrease in TG and apoAV in LPL-deficient mice.
The combined data suggest that apoAV levels follow TG lev-
els due to an intimate link between the apoAV molecule and
TG-rich lipoproteins, comprising both secretion and re-
moval of these lipoproteins. Taken together, the data sug-
gest that higher plasma apoAV levels reflect an increased
demand for plasma TG hydrolysis under normal physiologi-
cal conditions.—Vaessen, S. F. C., G. M. Dallinga-Thie, C. J. D.
Ross, L. J. Splint, L. W. Castellani, P. C. N. Rensen, M. R.
Hayden, F. G. Schaap, and J. A. Kuivenhoven. Plasma
apolipoprotein AV levels in mice are positively associated
with plasma triglyceride levels. J. Lipid Res. 2009. 50: 880–884.
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Since its discovery in 2001, apolipoprotein AV (apoAV)
has been postulated as a key regulator of plasma triglyc-
eride (TG) levels (1). Relevance for TG homeostasis was
initially demonstrated using genetically engineered mice:
Overexpression of human apoAV decreased plasma TG by
64%, while apoa5-deficient mice had 4-fold increased plasma
TG levels (1). In humans, it was furthermore shown that
variation at the APOA5 gene locus was associated with
TG levels (2–4), while complete apoAV deficiency was as-
sociated with severe hypertriglyceridemia (5, 6). Combined,
these data suggested that plasma levels of apoAV are in
general inversely correlated with TG levels. However, we
and others subsequently showed that plasma apoAV and
TG levels are, unexpectedly, positively correlated in pa-
tients with type 2 diabetes and in the general population
(7–11). Considering the suggested negative correlation be-
tween plasma apoAVand TG in mice, based on the overex-
pression models, these subsequent observations in humans
have led several investigators to suggest an inherent dif-
ference between humans and mice (10–12). This despite
the fact that the phenotypic presentation of complete
apoAV deficiency in mice and humans is similar (1, 5).
Moreover, in mice with endotoxemia (13) or in rats fed
PUFAs (14), semiquantification of apoAV levels by im-
munoblotting also suggested a positive correlation with
TG levels. In addition, Nelbach et al. (15) recently showed
a positive correlation between plasma apoAV and TG con-
centrations in mice overexpressing human apoAV. In this
study, we further addressed this hypothesis by determining
the relationship between plasma apoAV and TG levels in
wild-type mice and various genetically engineered mouse
models that are characterized by a wide range of elevated
levels of plasma triglycerides.
METHODS
Mouse models
To determine the association between plasma apoAV and TG
levels in mice, we collected plasma samples from different mouse
models on a C57BL/6 background with variable plasma TG lev-
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els. The etiology of increased TG levels in these mice and the col-
laborators who provided plasma samples are given below. Human
APOCI-transgenic-APOE3Leiden mice develop moderately ele-
vated plasma triglyceride levels due to an inhibition of LPL activ-
ity [n 5 16, courtesy of Dr. P. Rensen, Leiden University, Leiden,
the Netherlands (16)]. Glycosylphosphatidylinositol-anchored
HDL binding protein-deficient (Gpihbp12/2) mice are severely
hypertriglyceridemic because the lack of GPIHBP1 prevents bind-
ing of LPL to the vascular endothelium, resulting in an inability
to lipolyse triglycerides in apoB48- and apoB100-containing
lipoproteins [n 5 26, courtesy of Dr. S. Young and M. Weinstein,
University of California, Los Angeles, CA (17)]. Both murine
apoAII-transgenic (n 5 60) and murine apoAII-transgenic-apoE-
deficient mice (n 5 38) develop moderately elevated plasma
TG levels due to both an overproduction of VLDL by the liver
as well as an impaired LPL-mediated TG hydrolysis [both strains
are courtesy of Dr. L. Castellani, University of California, Los
Angeles, CA (18)]. Lpl2/2 mice develop severe hypertriglyc-
eridemia due to the inability to hydrolyze plasma triglycerides
(19). Plasma samples of heterozygous and homozygous lpl2/2
mice (both n 5 5) were provided by Dr. C. Ross [University
of British Columbia, Vancouver, Canada (19)]. To determine
whether an induced change in TG levels in mice affects apoAV
levels, we used plasma samples of lpl2/2 mice that were injected
intramuscularly with adeno-associated virus encoding the natural
variant LPL4473, as previously described (19). Wild-type mice (n 5
66), housed in our institute, were obtained from Harlan (Horst,
The Netherlands). Fasting (4–12 h) plasma samples of all mice
indicated above were prepared and immediately frozen at 280°C
at the respective institutions. The samples were sent on dry ice to
the laboratory in Amsterdam where they were stored at 280°C
until use for measurements.
Plasma TG and apoAV analyses
Plasma samples were analyzed for TG using a standard enzy-
matic assay (Roche, Basel, Switzerland). Murine apoAV levels were
determined using a newly developed ELISA. A rabbit-anti-rat
apoAV polyclonal antibody (20), with strong cross-reactivity to
murine apoAV, was used both as capture and biotinylated second-
ary antibody. Purified recombinant murine apoAV was used to
generate standard curves. Plates (Maxisorb, Nunc, Thermo Fisher
Scientific, Roskilde, Denmark) were coated overnight with the
capture antibody (100 ml, 5 mg/ml in 0.1 M carbonate buffer,
pH 9.6) at 4°C. After washing with PBX (PBS containing 0.1%
Triton X-100), wells were blocked for 1 h at room temperature
with PBXC (PBX containing 1% casein; Hammerstan grade,
Merck, Darmstadt, Germany). After extensive washing, wells were
incubated for 2 h with 100 ml of standard or sample (1:10) all di-
luted in PBXC. Next, wells were washed and incubated with 100 ml
of the biotinylated secondary antibody (2 mg/ml in PBXC) for 1 h.
Following washing, wells were incubated with streptavidin-horse-
radish peroxidase (1:5,000 in PBXC; DAKO, Glostrup, Denmark)
for 1 h. After extensive washing, the plate was incubated with
o-phenylenediamine dihydrochloride substrate (Sigma, St. Louis,
MO). The color reaction was stopped after exactly 10 min with
2 M sulfuric acid, and absorbance was read at 490 nm (Easia
reader, Medgenix Diagnostics, Springfield, MO). The inter-assay
variation coefficient was 3.7 6 1.6%.
Statistics
Statistics were performed using SPSS (version 16.0; Chicago,
IL). Concentrations are expressed as mean 6 SD. Plasma TG
levels show a skewed distribution; therefore, logarithmically trans-
formed values were used. Correlations between plasma apoAV
levels and TG levels were calculated using Pearson correlation.
Comparisons between pre- and posttreatment TG values of Lpl2/2
mice were performed using the Studentʼs t-test. P values , 0.05
were considered significant.
RESULTS
To determine the association between plasma apoAV and
TG levels in mice, we tested plasma samples from mouse
models with median TG levels ranging from 30 mg/dl
(range 13–88) in wild-type mice to 2089 mg/dl (range
200–6677) in gpihbp12/2 mice (Table 1). Figure 1 shows
that plasma apoAV and TG are positively correlated in mice
(r 5 10.798; P , 0.001) over the entire TG range. Table 1
shows that this positive correlation was observed in each of
the following subgroups: wild-type mice (r 5 10.368; P ,
0.01), gpihbp12/2 mice (r 5 10.455; P , 0.001), murine-
apoAII-transgenic mice (r 5 10.596; P , 0.001), and
murine-apoAII-transgenic-apoE2/2 mice (r 5 10.882; P ,
0.001). This correlation did not reach statistical signifi-
cance for the human APOCI-transgenic mice (r 5 10.2;
P 5 0.45), most likely due to the relative low number of
animals in this group. Thus, irrespective of the molecular
cause of hypertriglyceridemia, apoAV plasma levels are
positively correlated with plasma TG in mice.
To study apoAV in a context of changing TG levels, we
assessed plasma apoAV levels in lpl2/2 mice before and
after LPL gene transfer (19). We observed that apoAV was
elevated in lpl1/2 mice (TG of 110 6 52 mg/dl) and even
more so in lpl2/2 mice (TG levels of 5033 6 2141 mg/dl),
confirming our finding in the other mouse models (Fig. 2).
LPL gene transfer in lpl2/2 mice led to simultaneous sig-
nificant reductions of both TG and apoAV concentrations










Wild-type (n 5 66) 30.(13; 88) 24.6 14 10.368 ,0.010
Human-APOCI-transgenic (n 5 16) 297.(94; 464) 30.6 9 10.200 50.450
Gpihbp12/2 (n 5 26) 2089.(200; 6677) 147.6 30 10.455 ,0.010
Murine-apoAII-transgenic (n 5 60) 258.(54; 1360) 87.6 43 10.596 ,0.001
Murine-apoAII-transgenic-apoE2/2 (n 5 38) 182.(53; 1739) 111.6 47 10.882 ,0.001
a Data are presented as median (minimum; maximum).
b Data are represented as mean 6 SD.
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(Fig. 2), showing that induction of TG lowering is closely
followed by a decrease of apoAV levels.
DISCUSSION
This study provides unequivocal evidence for a positive
correlation between plasma apoAVand TG in mice, under-
lining that humans and mice are not different in this re-
gard as has been suggested by other investigators (10–
12). The current data also show that measuring apoAV
plasma levels does not provide direct biological insight
into the function of apoAV in vivo. It has been shown that
apoAV functions as a regulator for LPL to improve TG hy-
drolysis, at least in vitro (21, 22), and that apoAV may be
involved in remnant uptake (23, 24), both suggestive of a
role for apoAV in regulating TG levels. However, our cur-
rent data suggest that apoAV plasma levels change accord-
ing to changes in plasma TG levels.
The current data show that apoAV levels are positively
correlated with TG levels irrespective of the different ge-
netic causes of hypertriglyceridemia that were studied. This
correlation was present in mouse models with primary
defects in LPL-mediated TG hydrolysis: human APOCI-
transgenic mice in which overexpression of human apoCI
inhibits LPL-mediated TG hydrolysis (16), gpihbp12/2 mice
that lack the ability to bind LPL in the capillaries of the
heart, skeletal muscle and adipose tissue resulting in the
accumulation of chylomicrons and VLDL (17), and, finally,
lpl2/2 mice that cannot lipolyze plasma triglycerides in the
absence of LPL. In addition, the positive correlation was
also observed in animals with increased hepatic VLDL-TG
secretion in addition to a decreased LPL-mediated TG
hydrolysis. Specifically, the two murine apoAII-transgenic
strains have increased hepatic VLDL-TG secretion due to
increased hepatic lipogenesis and a reduced LPL-mediated
TG hydrolysis because the presence of apoAII makes VLDL
a poorer substrate for hydrolysis (18). A closer look into our
data furthermore revealed that apoAV plasma levels vary
strongly, especially relative to the observed TG levels, in
the different strains of mice. Specifically and relative to
TG levels, apoAV levels are only moderately elevated in
the gpihbp12/2 and lpl2/2 models, which present with the
highest TG levels. On the other hand, apoAV levels are
Fig. 2. LPL gene transfer simultaneously reduces TG and apoAV levels in Lpl-deficient mice. Plasma TG (A)
and apoAV (B) levels in lpl1/1, lpl1/2, lpl2/2-untreated, and adeno-associated virus-LPL-treated lpl2/2mice
4 weeks after treatment (19). * Significantly different (P , 0.05) compared with lpl2/2 mice that were not
treated with LPL gene transfer.
Fig. 1. Plasma apoAV and TG levels are positively correlated in mice. Correlation between log-transformed
plasma TG and apoAV levels in wild-type (n 5 66), human APOCI-transgenic (n 5 16), Gpihbp12/2 (n 5 26),
murine apoAII-transgenic (n 5 60), and murine apoAII-transgenic-apoE2/2 mice (n 5 38) (all on a C57Bl/6
background). Correlations within each group are presented in Table 1.
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more strongly increased in the APOAII-transgenic lines that
present with less severe hypertriglyceridemia. It thus ap-
pears that plasma apoAV levels are most intimately linked
to VLDL secretion and that the moderately elevated plasma
apoAV levels in models with primary defects in LPL hydro-
lysis reflect a delayed catabolism of chylomicrons and VLDL
particles. In line with this hypothesis, targeted reduction of
plasma TG through LPL gene therapy, i.e., increasing TG
hydrolysis in lpl2/2 mice, caused a concomitant decrease
in plasma apoAV levels This finding indicates that plasma
apoAV levels are thus also related to TG removal, as this
effect may be seen in the context of an apparently un-
changed VLDL-TG secretion in these animals (25). It is dif-
ficult to speculate on the cause for this phenomenon;
however, we wish to refer to the idea that apoAV-containing
lipoproteins are rapidly removed from the circulation after
LPL-mediated lipolysis that is induced upon binding to
GPIHBP1 (17). Nilsson et al. (26) recently showed that
apoAV binds to and is internalized via peripheral receptors
SorLA/LR11 and sortilin. It is thus conceivable that upon
increased TG hydrolysis after LPL gene therapy, apoAV
internalization is also increased, offering a possible explana-
tion for the decrease of plasma apoAV in our experiment.
Taken together, it appears that the positive correlation
of plasma apoAV with plasma TG levels is the result of an
intimate link between the apoAV molecule and TG-rich
lipoproteins that comprises both secretion and removal of
these lipoproteins. Current lines of evidence suggest that
apoAV is only synthesized in the liver, from which it is se-
creted into the circulation, a process that seems to be di-
rectly associated with the secretion of TG-rich VLDL. Upon
TG hydrolysis in VLDL in the plasma compartment, apoAV
is redistributed over all TG-rich lipoproteins, i.e., VLDL and
chylomicrons, as well as HDL (27) and, in mice, possibly
also LDL (15). HDL is thought to serve as a plasma reservoir
for apoAV as previously described for apoCs (28, 29) and
apoAII (18). In the postprandial state, this apoAV can trans-
fer to TG-rich lipoproteins to again facilitate TG hydrolysis.
Upon adequate TG hydrolysis and effective removal of
remnant lipoproteins from the circulation, apoAV is also
likely to be internalized and routed for degradation (26),
putatively after being reused as previously suggested (30).
In this light, we propose that increased plasma apoAV
levels may reflect an increased demand for plasma TG hy-
drolysis. However, it does not explain the observation that
mice overexpressing human apoAV have very low plasma
TG levels. In the latter situation, however, the physiological
regulation of plasma apoAV levels is overruled, and under
these conditions apoAV emerges as a primary regulator of
plasma TG levels due to its intrinsic TG-lowering capacity
(in the presence of active LPL). On the other hand, a recent
study also showed a positive relationship between plasma
apoAV and TG in mice that overexpress the human APOA5
gene, yet lack the murine apoa5 gene (15). However, this
correlation was observed with plasma human apoAV levels
50- to 100-fold higher compared with normal human plasma
apoAV concentrations. It will be interesting to see if a similar
correlation will be found in the context of lower apoAV
expression levels. On the other hand, previous murine stud-
ies suggesting a negative correlation between plasma apoAV
and TG were all performed under conditions of human
apoAVoverexpression in the presence of the murine apoAV
protein (1, 21). However, whether this difference contrib-
utes to the observed discrepancies between the murine
overexpression studies is unclear.
In conclusion, we show that plasma TG and apoAV levels
in mice are positively correlated, as previously observed in
humans, due to an intimate link between apoAV and TG-
rich lipoproteins that comprises both secretion and re-
moval pathways of these lipoproteins. The current data
suggest that apoAV levels follow TG levels, leading to the
hypothesis that increased plasma apoAV levels reflect an
increased demand for plasma TG hydrolysis under physio-
logical conditions.
The authors would like to thank Prof. Stephen G. Young and
Michael Weinstein (Division of Cardiology, Department of Med-
icine, David Geffen School of Medicine, UCLA) for providing
the plasma samples of the GPIHBP1-deficient mice.
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